Evidence map›Paper›PMID 35672242›Full record

ArticleTrends in cancer2022

Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance.

Blaire E Barton, Cindy H Chau, William D Figg

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Blaire E BartonMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cindy H ChauMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
William D FiggMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: figgw@mail.nih.gov.

Funding

Drug Development for Prostate Cancer and other Metastatic ProcessesZIABC010547 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$10.2M
Development of Drugs That Target Prostate CancerZ01BC010547 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2003 to 2008
$463k
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZ01SC006537 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$379k
Intramural NIH HHS Z01 BC010547Intramural NIH HHS Z01 SC006537Intramural NIH HHS ZIA BC010547
6 · The paper itself

Abstract

Checkpoint blockade and adoptive T cell therapy are efficacious in some patients, but many do not respond to these immunotherapies. Chou et al. recently elucidated the characteristics of a new cell population with greater cytotoxicity, improved tumor homing, and reduced exhaustion compared to conventional cytotoxic T cells. These cells may improve the efficacy of cancer immunotherapies, especially for patients refractory or unresponsive to current approaches.

Indexed as

Immunotherapy, AdoptiveNeoplasmsHumansMonitoring, ImmunologicT-Lymphocytes, Cytotoxicimmunosurveillanceimmunotherapyinnate-like cytotoxic T cellsT cell exhaustiontumor homing

Identifiers

PMID35672242
PMCPMC9308744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.